Aurinia Pharmaceuticals Inc.
AUPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,516 | $1,177 | $1,117 | $1,277 |
| - Cash | $73 | $53 | $66 | $83 |
| + Debt | $78 | $82 | $78 | $79 |
| Enterprise Value | $1,521 | $1,205 | $1,128 | $1,273 |
| Revenue | $73 | $70 | $62 | $60 |
| % Growth | 4.9% | 12.1% | 4.3% | – |
| Gross Profit | $65 | $63 | $54 | $54 |
| % Margin | 88.4% | 89.8% | 86.3% | 90.7% |
| EBITDA | $37 | $28 | $30 | $7 |
| % Margin | 50.1% | 40.2% | 48.5% | 12% |
| Net Income | $32 | $22 | $23 | $1 |
| % Margin | 42.9% | 30.7% | 37.4% | 2.4% |
| EPS Diluted | 0.23 | 0.15 | 0.16 | 0.01 |
| % Growth | 53.3% | -6.3% | 1,500% | – |
| Operating Cash Flow | $44 | $44 | $1 | $30 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $44 | $44 | $1 | $30 |